Apollomics announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress 2023, held in Madrid, Spain from October 20-24, 2023. The patient with GBM with PTPRZ-MET fusion who had previously received radiotherapy and temozolomide, was reported to have an impressive Partial Response after 8 weeks of treatment with vebreltinib monotherapy during participation in the SPARTA study. GBM with MET fusion is an indication pursued by Apollomics and its China partner, Avistone Biotechnology. Avistone sponsors an active-controlled phase 2/3 study of vebreltinib for the treatment of GBM with PTPRZ-MET fusion, and has been in communication with the National Medical Products Administration regarding a supplemental New Drug Application (NDA) for this indication and has recently received priority review from the NMPA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLM:
- Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
- Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
- Apollomics announces efficacy of vebreltinib in NSCLC patients
- Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
- Apollomics price target lowered to $17 from $18 at H.C. Wainwright